Gusacitinib

DB15670InvestigationalSmall molecule

Gusacitinib is under investigation in clinical trial NCT02550678 (A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma).

Mechanism: Pharmacologically active on Tyrosine-protein kinase SYK and Janus (JAK) kinases
Curator reviewed
Formula / weight: C₂₄H₂₈N₈O₂ · 460.542 g/mol (avg)
Also known as: 1-(4-(4-(4-HYDROXY-PIPERIDIN-1-YL)-PHENYLAMINO)-5-OXO-5,6-DIHYDRO-PYRIMIDO(4,5-D)PYRIDAZIN-2-YL)-PIPERIDIN-4-YL-ACETONITRILE
Code names: ASN-002 · EN-3351 · WHO 10976

Resolves to

Compound

UNII4801QYW816CAS1425381-60-7ChEMBLCHEMBL4594275

Structure

InChIKeyNLFLXLJXEIUQDL-UHFFFAOYSA-NSMILESOC1CCN(CC1)C1=CC=C(NC2=C3C(=O)NN=CC3=NC(=N2)N2CCC(CC#N)CC2)C=C1

Targets

P43405SYK

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

10Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Gusacitinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account